Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 4/2020

01-12-2020 | Gastric Cancer | Non-Thematic Review

Gastric cancer: a comprehensive review of current and future treatment strategies

Authors: Rachel E. Sexton, Mohammed Najeeb Al Hallak, Maria Diab, Asfar S. Azmi

Published in: Cancer and Metastasis Reviews | Issue 4/2020

Login to get access

Abstract

Gastric cancer remains a major unmet clinical problem with over 1 million new cases worldwide. It is the fourth most commonly occurring cancer in men and the seventh most commonly occurring cancer in women. A major fraction of gastric cancer has been linked to variety of pathogenic infections including but not limited to Helicobacter pylori (H. pylori) or Epstein Barr virus (EBV). Strategies are being pursued to prevent gastric cancer development such as H. pylori eradication, which has helped to prevent significant proportion of gastric cancer. Today, treatments have helped to manage this disease and the 5-year survival for stage IA and IB tumors treated with surgery are between 60 and 80%. However, patients with stage III tumors undergoing surgery have a dismal 5-year survival rate between 18 and 50% depending on the dataset. These figures indicate the need for more effective molecularly driven treatment strategies. This review discusses the molecular profile of gastric tumors, the success, and challenges with available therapeutic targets along with newer biomarkers and emerging targets.
Literature
1.
2.
3.
4.
5.
6.
Miaozhen, Q., Zhou, Y., Zhang, X., Wang, Z., Wang, F., Shao, J., Lu, J., Jin, Y., Wei, X., Zhang, D., et al. (2014). Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients. BMC Cancer, 14(823). https://​doi.​org/​10.​1186/​1471-2407-14-823.
7.
8.
Petrelli, F., Berenato, R., Turati, L., Mennitto, A., Steccanella, F., Caporale, M., Dallera, P., de Braud, F., Pezzica, E., Di Bartolomeo, M., et al. (2017). Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. Journal of Gastrointestinal Oncology., 8(1).
9.
Rugge, M., Fassan, M., & Graham, D. Y. (2015). Epidemiology of Gastric Cancer. Gastric Cancer, 23–34.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
Jones, K. R., Joo, Y. M., Jang, S., Yoo, Y. J., Lee, H. S., Chung, I. S., Olsen, C. H., Whitmire, J. M., Merrell, S., & Cha, J. H. (2009). Polymorphism in the CagA EPIYA motif impacts development of gastric cancer. Journal of Clinical Microbiology, 959–968. https://​doi.​org/​10.​1128/​JCM.​02330-08.
20.
Kim, K. E. (2003). Gastric cancer in Korean Americans: risks and reductions. Korean Korean Am Stud Bull, 13(1/2), 84–90 PMCID: 1592326.PubMedPubMedCentral
21.
22.
23.
24.
25.
26.
27.
Josefson, D. (2001). Prophylactic gastrectomy seems to extend life of patients with a family history of stomach cancer. BMJ, 322(7302), 1566 PMCID: PMC1173358.CrossRef
28.
Ferro, A., Rosato, V., Rota, M., Costa, A. R., Morais, S., Pelucchi, C., Johnson, K. C., Hu, J., Palli, D., Ferraroni, M., et al. (2019). Meat intake and risk of gastric cancer in the stomach cancer pooling (StoP) project. International Journal of Cancer. https://​doi.​org/​10.​1002/​ijc.​32707.
29.
30.
31.
Praud, D; Rota, M; Pelucchi, C; Bertuccio, P; Rosso, T; Galeone, C; Zhang, Z.F; Matsuo, K Ito, H; Hu, J; et al. Cigarette smoking and gastric cancer in the Stomach Cancer Pooling (StoP) project. European Journal of Cancer Prevention 2018; 27(2): 124–133. DOI: https://​doi.​org/​10.​1097/​CEJ.​0000000000000290​.
32.
Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., Meyer, L., Gress, D. M., Byrd, D. R., & Winchester, D. P. (2017). The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA: a Cancer Journal for Clinicians, 67(2), 93–99. https://​doi.​org/​10.​3322/​caac.​21388.CrossRef
33.
34.
35.
36.
Sasako, M., Sakuramoto, S., Katai, H., Kinoshita, T., Furukawa, H., Yamaguchi, T., Nashimoto, A., Fujii, M., Nakajima, T., & Ohashi, Y. (2011). Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. Journal of Clinical Oncology, 29(33), 4387–4393. https://​doi.​org/​10.​1200/​JCO.​2011.​36.​5908.CrossRefPubMed
37.
38.
Jayanathan, M., Erwin, R. P., Molacek, N., Fluck, M., Hunsinger, M., Wild, J., Arora, T. K., Shabahang, M. M., Franko, J., & Blansfield, J. A. (2019). MAGIC versus MacDonald treatment regimes for gastric cancer: Trends and predictors of multimodal therapy for gastric cancer using the National Cancer Database. American Journal of Surgery. https://​doi.​org/​10.​1016/​j.​amjsurg.​2019.​06.​005.
39.
40.
Webb, A., Cunningham, D., Scarffe, J. H., Harper, P., Norman, A., Joffe, J. K., Hughes, M., Mansi, J., Findlay, M., et al. (1997). Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. Journal of Clinical Oncology, 15(1), 261–267.CrossRef
41.
Cunningham, D., Starling, N., Rao, S., Iveson, T., Nicolson, M., Coxon, F., Middleton, G., Daniel, F., Oates, J., & Norman, A. R. (2008). Capecitabine and oxaliplatin for advanced esophagogastric cancer. The New England Journal of Medicine, 358, 36–46.CrossRef
42.
Al-Batran, S. E., Homann, N., Pauligk, C., Goetze, T. O., Meiler, J., Kasper, S., Koop, H. G., Mayer, F., Haag, G. M., Luley, K., et al. (2019). Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, rescectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomized, phase 2/3 trial. Lancet., 393(10184), 1948–1957. https://​doi.​org/​10.​1016/​S0140-6736(18)32557-1.CrossRefPubMed
43.
44.
Ahn, H. S., Jeong, S. H., Son, Y. G., Lee, H. J., Im, S. A., Bang, Y. J., Kim, H. H., & Yang, H. K. (2014). Effect of neoadjuvant chemotherapy on postoperative morbidity and mortality in patients with locally advanced gastric cancer. The British Journal of Surgery, 101(12), 1560–1565. https://​doi.​org/​10.​1002/​bjs.​9632.CrossRefPubMed
45.
Al-Batran, S.-E., Hofheinz, R. D., Schmalenberg, H., Strumberg, D., Goekkurt, E., Angermeier, S., Zander, T., Potenberg, J., Koop, H. G., Pink, D., et al. (2020). Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7): results of the phase II-portion—a multicenter, randomized phase II/III trial of the German AIO and Italian GOIM. Journal of Clinical Oncology, 38(15).
46.
Hofheinz, R. D., Haag, G. M., Ettrich, T. J., Borchert, K., Kretzschmar, A., Teschendorf, C., Siegler, G. M., Ebert, M. P., Goekkurt, E., Welslau, M., et al. (2020). Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma: final results of the PETRARCA multicenter randomized phase II trail of the AIO. Journal of Clinical Oncology, 35(18).
47.
Bang Y.J.; Kim, Y.W.; Yang, H.K.; Chung, H.C.; Park, Y.K.; Lee, K.H.; Kim, Y.H; Noh, S.I.; Cho, J.Y.; et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomized controlled trial. The Lancet (British edition). 2012;379(9813):315–321. DOI: https://​doi.​org/​10.​1016/​S0140-6736(11)61873-4.
48.
Bang, Y. J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. The Lancet., 376(9742), 687–697. https://​doi.​org/​10.​1016/​S0140-6736(10)6121-X.CrossRef
49.
50.
An Cutsem, E., Muro, K., Cunningham, D., Bodoky, G., Sobrero, A., Cascinu, S., Ajani, J., Al-Batran, S. E., Wainberg, Z. A., Wijayawardana, S. R., et al. (2020). Biomarker analyses of second-line Ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study. European Journal of Cancer, 127, 150–157. https://​doi.​org/​10.​1016/​j.​ejca.​2019.​10.​026.CrossRefPubMed
51.
FDA grands accelerated approval to pembrolizumab for first tissue/site agnostic indication. FDA. Accessed July 28, 2020.G.
52.
Fuchs, C. S., Doi, T., Jang, R. W., Muro, K., Satoh, T., Machado, M., Sun, W., Jalal, S. I., Shah, M. A., Metges, J. P., et al. (2018). Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE- 059 trial. JAMA Oncology, 4, e180013.CrossRef
53.
FDA approves pembrolizumab for adults and children with TMB-H solid tumors. (2020). FDA. Accessed July, 25.
54.
55.
56.
57.
Ferguson, F. M., & Gray, N. S. (2018). Kinase inhibitors: the road ahead. Nature Reviews. Drug Discovery, 17, 353–377.CrossRef
58.
59.
60.
Gotink, K.J.; Broxterman, H.J.; Labots, M; de Haas, R.R.; Dekker, H; Honeywell, R.J.; Rudek, M.A.; Beerepoot, L.V.; Musters, R.J; Jansen, G; et al. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clinical Cancer Research 2011; 17(23):7337–7346. DOI: https://​doi.​org/​10.​1158/​1078-0432.​CCR-11-1667.
61.
Guo, T; Hajdu, M; Agaram, N.P.; Shinoda, H; Veach, D; Clarkson, B.D.; Maki, R.G.; Singer, S; DeMatteo, R.P.; Besmer, P; et al. Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug-resistance. Clinical Cancer Research 2009; 15(22): 6862–6870. DOI: https://​doi.​org/​10.​1158/​1078-0432.​CCR-09-1315.
62.
63.
Boland, P. M., Meyer, J. E., Berger, A. C., Cohen, S. J., Neuman, T., Cooper, H. S., Olszanski, A. J., Davey, M., Cheng, J. D., Lebenthal, A., et al. (2018). Induction therapy for locally advanced, resectable esophagogastric cancer: A phase I trial of vandetanib (ZD6474), paclitaxel, carboplatin, 5-fluorouracil and radiotherapy followed by resection. American Journal of Clinical Oncology, 40(4), 393–398. https://​doi.​org/​10.​1097/​COC.​0000000000000171​.CrossRef
64.
65.
66.
67.
68.
69.
70.
Marin, J. J., Al-Abdulla, R., Lozano, E., Briz, O., Bujanda, L., Banales, J. M., & Macias, R. I. (2016). Mechanisms of resistance to chemotherapy in gastric cancer. Anti-Cancer Agents in Medicinal Chemistry, 16(3), 318–334.CrossRef
71.
Meehan, R. S., & Chen, A. P. (2016). New treatment option for ovarian cancer: PARP inhibitors. Gynecologic Oncology Research and Practice., 7(3).
72.
73.
74.
Bang, Y.J.; Xu, R.H.; Chin, K; Lee, K.W.; Park, S.H.; Rha, S.Y.; Shen, L; Qin, S; Xu, N; Im, S.A; et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): A double-blind, randomized, placebo-controlled, phase 3 trial. Oncology. 2017; 18(12): 1637–1651. DOI: https://​doi.​org/​10.​1016/​S1470-2045(17)30682-4.
75.
Cechini, M., LoRusso, P., Shyr, Y., Ivy, P., Sklar, J., Dooley, K., & Lacy, J. (2018). NCI 10066: A phase I-II study of Olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology, 36(15).
76.
Jang, J. Y., Kang, Y. J., Sung, B., Kim, M. J., Park, C., Kang, D., Moon, H. R., Chung, H. Y., & Kim, N. D. (2018). MHY440, a novel topoisomerase I inhibitor, induces cell cycle arrest and apoptosis via a ROS-dependent DNA damage signaling pathway in AGS human gastric Cancer cells. Molecules, 24(1), E96. https://​doi.​org/​10.​3390/​molecules2401009​6.CrossRefPubMed
77.
Yi, H., Yan, X., Luo, Q., Yuan, L., Li, B., Pan, W., Zhang, L., Chen, H., Wang, J., Zhang, Y., et al. (2018). A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma. Journal of Experimental & Clinical Cancer Research, 37(1), 97. https://​doi.​org/​10.​1186/​s13046-018-0765-8.CrossRef
78.
79.
Fok, J. H., Ramos-Montoya, A., Vazquez-Chantada, M., Wijnhoven, P. W. G., Follia, V., James, N., Farrington, P. M., Karmokar, A., Willis, S. E., Cairns, J., et al. (2019). AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity. Nature Communications, 10(5065).
80.
Tamura, T., Ohira, M., Tanaka, H., Muquruma, K., Toyokawa, T., Kubo, N., Sakurai, K., Amano, R., Kimura, K., Shibutani, M., et al. (2015). Programmed death-1 ligand-1 (PDL1) expression is associated with the prognosis of patients with stage II/III gastric Cancer. Anticancer Research, 35(10), 5369–5376.PubMed
81.
B; Mondaca, S; Sanchez, C; Galindo, H; Nervi, B; Ibanez, C; et al. High proportion of potential candidates for immunotherapy in a Chilean cohort of gastric cancer patients: results of the FORCE1 Study. Cancers (Basel). 2019; 11(9): E1275. DOI: https://​doi.​org/​10.​3390/​cancers11091275.
82.
Lee, H. S., Chang, M. S., Yang, H. K., Lee, B. L., & Kim, W. H. (2004). Epstein-Barr virus-positive gastric carcinoma has a distinct protein expression profile in comparison with Epstein-Barr virus-negative carcinoma. Clinical Cancer Research, 10, 1698–1705.CrossRef
83.
Fuchs, C.S.; Doi, T; Jang, R.W.; Muro, K; Satoh, T; Machado, M; Sun, W; Jalal, S.I.; Shah, M.A.; Metges, J.P.; et al. Safety and efficacy of Pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical keynote-059 trial. JAMA Oncology 2018; 4(5):e180013. DOI: https://​doi.​org/​10.​1001/​jamaoncol.​2018.​0013.
84.
Xing, X., Guo, J., Ding, G., Li, B., Dong, B., Feng, Q., Li, S., Zhang, J., Ying, X., Cheng, X., et al. (2017). Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. Oncoimmunology, 7(3), e1356114 DOI: 1080/2162402X.2017.1356144.
85.
Kang, Y. K., Boku, N., Satoh, T., Ryu, M. H., Chao, Y., Kato, K., Chung, H. C., Chen, J. S., Muro, K., Kang, W. K., et al. (2017). Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomized, double-blind, placebo controlled, phase 3 trial. The Lancet., 390(10111), 2461–2471. https://​doi.​org/​10.​1016/​S0140-6736(17)31827-5.CrossRef
86.
Hara, H., Shoji, H., Takahari, D., Esaki, T., Machida, N., Nagashima, K., Aoki, K., Honda, K., Miyamoto, T., Boku, N., et al. (2019). Phase I/II study of ramucirumab plus nivolumab in patients in second-line treatment for advanced gastric adenocarcinoma (NivoRam study). Journal of Clinical Oncology, 37(4).
87.
88.
Ham, I. H., Oh, H. J., Jin, H., Bae, C. A., Jeon, S. M., Choi, K. S., Son, S. Y., Han, S. U., Brekken, R. A., Lee, D., & Hur, H. (2019). Targeting interleukin-6 as a stragety to overcome stroma-induced resistance to chemotherapy in gastric cancer. Molecular Cancer, 18(68).
89.
90.
91.
Khawar, M. B., Abbasi, M. H., & Sheikh, N. (2016). IL-32: A novel pluripotent inflammatory interleukin, towards gastric inflammation, gastric cancer, and chronic rhino sinusitis. Mediators of Inflammation.
92.
93.
Zhan, X., Wang, B., Li, L., Li, J., Wang, H., Chen, L., Jiang, H., Wu, M., Xiao, J., Peng, X., et al. (2019). Phase I trial of Claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and pancreatic adenocarcinoma. Journal of Clinical Oncology, 37(15).
94.
Clinicaltrials.​gov. Intraperitoneal infusion of EpCAM CAR-T cell in advanced gastric cancer with peritoneal metastasis. Identifier: NCT03563326.
95.
Lu, J., Xu, Y., Wu, Y., Huang, X. Y., Xie, J. W., Wang, J. B., Lin, J. X., Zheng, C. H., Huang, A. M., & Huang, C. M. (2019). Tumor-inflitrating CD8+ T cells combined with tumor-associated CD68+ macrophages predict postoperative prognosis and adjuvant chemotherapy benefit in resected gastric cancer. BMC Cancer, 19(920).
96.
97.
98.
Lin, H. J. (2015). Cancer-associated fibroblasts: their characteristics and their roles in tumor growth. Cancers (Basel), 7(4), 2443–2458.CrossRef
99.
100.
101.
102.
Jiang, Y; Xie, J; Huang, W; Chen, H; Xi, S; Han, Z; Huang, L; Lin, T; Zhao, L.Y.; Hu, Y.F.; et al. Tumor immune microenvironment and chemosensitivity signature for predicting response to chemotherapy in gastric cancer. Cancer Immunol Res. 2019; 7(12): 2065–73. DOI: https://​doi.​org/​10.​1158/​2326-6066. CIR-19-0311.
103.
104.
105.
106.
107.
108.
109.
Zhou, Q., Wu, X., Wang, X., Yu, Z., Pan, T., Li, Z., Chang, X., Jin, Z., Li, J., Zhu, Z., Liu, B., & Su, L. (2020). The reciprocal interaction between tumor cells and activated fibroblasts mediated by TNF-a/IL-33/ST2L signaling promotes gastric cancer metastasis. Oncogene, 39(7), 1414–1428. https://​doi.​org/​10.​1038/​s41388-019-1078-x.CrossRefPubMed
110.
111.
112.
113.
Ding, X., Ji, J., Jiang, J., Cai, Q., Wang, C., Shi, M., Yu, Y., Zhu, Z., & Zhang, J. (2018). HGF-mediated crosstalk between cancer-associated fibroblasts and MET-unamplified gastric cancer cells activates coordinated tumorigenesis and metastasis. Cell Death & Disease, 9(9), 867. https://​doi.​org/​10.​1038/​s41419-018-0922-1.CrossRef
114.
115.
Wang, X., Zhou, Q., Yu, Z., Wu, X., Chen, X., Li, J., Li, C., Yan, M., Zhu, Z., Liu, B., & Su, L. (2017). Cancer-associated fibroblast-derived Lumican promotes gastric cancer progression via the integrin B1-FAK signaling pathway. International Journal of Cancer, 141(5), 998–1010. https://​doi.​org/​10.​1002/​ijc.​30801.CrossRefPubMed
116.
117.
118.
119.
Sun, Z., Cai, S., Liu, C., Cui, Y., Ji, J., Jiang, W. G., & Ye, L. (2020). Increased expression of Gremlin1 promotes proliferation and epithelial mesenchymal transition in gastric cancer cells and correlates with poor prognosis of patients with gastric cancer. Cancer Genomics & Proteomics, 17(1), 49–60. https://​doi.​org/​10.​21873/​cgp.​20167.CrossRef
120.
121.
122.
123.
Lei, Z., Chai, N., Tian, M., Zhang, Y., Wang, G., Liu, J., Tian, Z., Yi, X., Chen, D., Li, X., et al. (2018). Novel peptide GX1 inhibits angiogenesis by specifically binding to transflutaminase-2 in the tumorous endothelial cells of gastric cancer. Cell Death & Disease, 9(6), 579. https://​doi.​org/​10.​1038/​s41419-018-0594-x.CrossRef
124.
125.
126.
Bull, M. J., & Plummer, N. T. (2014). Part 1: the human gut microbiome in health and diseases. Interreg Mediterranean (Encinitas)., 13(6), 17–22.
127.
128.
Oliphant, K., & Allen-Vercoe, E. (2019). Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health. Microbiome., 7(91).
129.
Abenavoli, L; Scarpellini, E; Colica, C; Boccuto, L; Salehi, B; Sharifi-rad J; Aiello, V; Romano, B; De Lorenzo, A; Izzo, A.A.; et al. Gut microbiota and obesity: a role for probiotics. Nutrients 2019;11(11):2690. DOI: https://​doi.​org/​10.​3390/​nu11112690.​
130.
131.
132.
133.
134.
135.
136.
137.
Spanguolo, C., Russo, G. L., Orhan, I. E., Habtemariam, S., Dagila, M., Sureda, A., Nabavi, S. F., Devi, K. P., Loizzo, M. R., Tundis, R., et al. (2015). Genistein and cancer: current status, challenges, and future directions. Advances in Nutrition, 6(4), 408–419. https://​doi.​org/​10.​3945/​an.​114.​008052.CrossRef
138.
139.
140.
141.
142.
143.
144.
145.
Coker, O. O., Dai, Z., Nie, Y., Zhao, G., Cao, L., Nakatsu, G., Wu, W. K. K., Wong, S. H., Chen, Z., Sung, J. J. Y., & Yu, J. (2017). Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut.
146.
147.
148.
149.
150.
151.
152.
153.
Quaresma, M., Damasceno, S., Monteiro, C., Lima, F., Mendes, T., Lima, M., Justino, P., Barbosa, A., Souza, M., Souza, E., et al. (2019). Probiotic mixture containing Lactobacillus spp. and Bifidobacterium spp. attenuates 5-fluorouracil-induced intestinal mucositis in mice. Nutrition and Cancer, 1–11. https://​doi.​org/​10.​1080/​01635581.​2019.​167519.​
154.
155.
156.
157.
158.
Pavai, S., & Yap, S. F. (2003). The clinical significance of elevated levels of serum CA 19-9. The Medical Journal of Malaysia, 58(5), 667–672.PubMed
159.
160.
Iwasaki, H., Shimura, T., Yamada, T., Okuda, Y., Natsume, M., Kitagawa, M., Horike, S., & Kataoka, H. (2019). A novel urinary microRNA biomarker panel for detecting gastric cancer. Journal of Gastroenterology, 54, 1061–1069.CrossRef
161.
Sexton, R., Mahdi, Z., Chaudhury, R., Beydoun, R., Aboukameel, A., Khan, H. Y., Baloglu, E., Senapedis, W., Landesman, Y., Tesfaye, A., Kim, S., Philip, P. A., & Azmi, A. S. (2019). Targeting nuclear exporter protein XPO1/CRM1 in gastric cancer. International Journal of Molecular Sciences, 20(19), E4826. https://​doi.​org/​10.​3390/​ijms20194826.CrossRefPubMed
162.
163.
164.
165.
Yao, X. M., Tang, J. H., Zhu, H., & Jing, Y. (2017). High expression of LncRNA CASC15 is a risk factor for gastric cancer prognosis and promote the proliferation of gastric cancer. European Review for Medical and Pharmacological Sciences, 21, 5661–5667.PubMed
166.
167.
168.
169.
170.
171.
172.
173.
174.
175.
176.
177.
178.
179.
180.
181.
182.
183.
184.
185.
186.
187.
188.
189.
190.
191.
192.
193.
194.
195.
196.
197.
198.
Fukamachi, H., Kim, S. K., Koh, J., Lee, H. S., Sasaki, Y., Yamashita, K., Nishikawaji, T., Shimada, S., Akiyama, Y., Byeon, S. J., et al. (2019). A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors. Journal of Experimental & Clinical Cancer Research, 38(127).
199.
200.
Ohtsu, A; Ajani, J.A.; Bai, Y.X.; Bang, Y.J.; Chung, H.C.; Pan, H.M.; Sahmoud, T; Shen, L; Yeh, K.H.; Chin, K; et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double blind, phase III GRANITE-1 study. Gastrointestinal Cancer. 2013; 31: 3935–3943. DOIL https://​doi.​org/​10.​1200/​JCO.​2012.​48.​3552.
201.
202.
203.
Rong, L., Li, Z., Leng, X., Li, H., Ma, Y., Chen, Y., & Song, F. (2020). Salidroside induces apoptosis and protective autophagy in human gastric cancer AGS cells through the PI3K/Akt/mTOR pathway. Biomedicine & Pharmacotherapy, 122, 109726.CrossRef
204.
Liu, J., Zhang, Y., Qu, J., Xu, L., Hou, K., Zhang, J., Qu, X., & Liu, Y. (2011). B-Elemene-induced autophagy protects human gastric cancer cells from undergoing apoptosis. BMC Cancer, 11(183).
205.
206.
Zhang, Y., Liu, S., Feng, Q., Huang, X., Wang, X., Peng, Y., Zhao, Z., & Liu, Z. (2018). Perialdehyde activates AMP-activated protein kinase to suppress the growth of gastric cancer via induction of autophagy. Journal of Cellular Biochemistry. https://​doi.​org/​10.​1002/​jcb.​27491.
207.
208.
209.
210.
211.
212.
213.
214.
215.
Zou, P., Xia, Y., Chen, T., Zhang, J., Wang, Z., Chen, W., Chen, M., Kanchana, K., Yang, S., & Liang, G. (2015). Selective killing of gastric cancer cells by small molecule targeting ROS-mediated ER stress activation. Molecular Carcinogenesis. https://​doi.​org/​10.​1002/​mc.​22351.
216.
217.
218.
219.
220.
Liu, X., Nie, W., Liang, J., & Li, Y. (2017). Interaction of Helicobacter pylori with other microbiota species in the development of gastric cancer. Clinical Microbiology.
221.
222.
223.
Hsieh, Y. Y., Tung, S. Y., Pan, H. Y., Yen, C. W., Xu, H. W., Lin, Y. J., Deng, Y. F., Hsu, W. T., Wu, C. S., & Li, C. (2018). Increased abundance of Clostridium and fusobacterium in gastric microbiota of patients with gastric cancer in Taiwan. Scientific Reports, 8(158).
224.
Roberts, P. J., Dickinson, R. J., Whitehead, A., Laughton, C. R., & Foweraker, J. E. (2002). The culture of lactobacilli species in gastric carcinoma. Journal of Clinical Pathology, 55, 477–480.CrossRef
225.
226.
227.
228.
229.
230.
231.
Rebecca, V. W., Nicastri, M. C., Fennelly, C., Chude, C. L., Barber-Rotenberg, J. S., Ronghe, A., McAfee, Q., McLaughlin, N. P., Zhang, G., Goldman, A. R., et al. (2018). PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. AACR Journals. Published. https://​doi.​org/​10.​1158/​2159-8290.​CD-18-0706.
232.
233.
Mahameed, M., Wilhelm, T., Darawshi, O., Obiedat, A., Tommy, W. S., Chintha, C., Schubert, T., Samali, A., Chevet, E., et al. (2019). The unfolded protein response modulators GSK2606414 and KIRA6 are potent KIT inhibitors. Cell Death & Disease, 10(300).
234.
Axten, J. M., Romeril, S. P., Shu, A., Ralph, J., Medina, J. R., Feng, Y., Li, W. H. H., Grant, S. W., Heerding, D. A., et al. (2013). Discovery of GSK2656157: An optimized PERK inhibitor selected for preclinical development. ACS Medicinal Chemistry Letters. https://​doi.​org/​10.​1021/​ml400228e.
235.
Li, J., Tu, H. J., Li, J., Dai, G., Dai, Y. C., Wu, Q., Shi, Q. Z., Cao, Q., & Li, Z. J. (2007). N-acetyl cysteine inhibits human signet ring cell gastric cancer cell line (SJ-89) cell growth by inducing apoptosis and DNA synthesis arrest. European Journal of Gastroenterology & Hepatology, 19(9), 769–774. https://​doi.​org/​10.​1097/​MEG.​0b013e3292202bda​.​CrossRef
236.
237.
Chen, X., Mao, G., Chen, H., Liu, S., Wang, S., Li, X., Ye, Y., Wu, H., & Liu, J. (2018). TW37 enhances the pro-apoptosis and anti-migratory ability of gefitinib in non-small cell lung cancer. Molecular and Cellular Biology (Noisy-le-grand)., 64(4), 6–10.CrossRef
238.
239.
Manero, F., Gautier, F., Gallenne, T., Cauquil, N., Gree, D., Catron, P. F., Geneste, O., Gree, R., Vallette, F. M., & Juin, P. (2006). The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Research, 66(5), 2757–2764.CrossRef
240.
Chang, J., Wang, Y., Shao, L., Laberge, R. M., Demaria, M., Campisi, J., Janakiraman, K., Sharpless, N. E., Ding, S., Feng, W., et al. (2016). Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nature Medicine, 22(1), 78–83.
241.
Zhang, H., Zhong, X., Zhang, X., Shang, D., Zhou, Y. I., & Zhang, C. (2016). Enhanced anticancer effect of ABT-737 in combination with naringenin on gastric cancer cells. Experimental and Therapeutic Medicine, 11(2), 669–673.CrossRef
Metadata
Title
Gastric cancer: a comprehensive review of current and future treatment strategies
Authors
Rachel E. Sexton
Mohammed Najeeb Al Hallak
Maria Diab
Asfar S. Azmi
Publication date
01-12-2020
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 4/2020
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-020-09925-3

Other articles of this Issue 4/2020

Cancer and Metastasis Reviews 4/2020 Go to the issue

Non-Thematics Review

Rho GTPases in cancer radiotherapy and metastasis

Editorial

A perspective on the early days of RAS research

ReviewPaper

Dynamically encoded reactivity of Ras enzymes: opening new frontiers for drug discovery

ReviewPaper

K-Ras prenylation as a potential anticancer target

Non-Thematics Review

Molecular mediators of peritoneal metastasis in pancreatic cancer

ReviewPaper

Molecular epidemiology and diagnostics of KRAS mutations in human cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits